You are here:

Reuters Features Medical Marijuana, Inc.’s Major Investment …

The article states: “The companies are targeting more than 100 million Americans who suffer from chronic pain, and are dependent on opioid painkillers such as Vicodin, or addicted to street opiates including heroin.”

“We are grateful that Reuters is covering companies like AXIM that are developing alternatives for the roughly 2.5 million Americans addicted to opioids,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “The future of pain management, a $100 billion market, may be a high dose of cannabis and a low dose of opioids. Already, we are seeing the incidence of prescription drug overdose death 25% lower in states where medical cannabis is legal, presumably because patients are able to combine natural botanical cannabis and use lower dose opioids to control pain.”

On June 23, 2017, AXIM Biotech announced that it filed with the United States Patent and Trademark Office (USPTO) for U.S. Application Serial Number